Print

Purpose

The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.

Condition

Eligibility

Eligible Ages
Between 18 Years and 55 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Female individuals not of childbearing potential and males. - Healthy as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments. - 18 to 55 years of age, inclusive, at the time of signing the informed consent with a BMI 18.0 to 32.0 kg/m2, inclusive. - Other protocol-defined Inclusion/

Exclusion Criteria

apply.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Treatment A
  • Drug: BMS-986278
    Specified dose on specified days
Experimental
Treatment B
  • Drug: BMS-986278
    Specified dose on specified days
  • Drug: Placebo
    Specified dose on specified days
Placebo Comparator
Treatment C
  • Drug: Placebo
    Specified dose on specified days
Experimental
Treatment D
  • Drug: Placebo
    Specified dose on specified days
  • Drug: Moxifloxacin
    Specified dose on specified days

Recruiting Locations

Worldwide Clinical Trials
San Antonio, Texas 78217
Contact:
Alan Hand, Site 0001
210-635-1515

More Details

Status
Recruiting
Sponsor
Bristol-Myers Squibb

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.